Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Norway

Marie Skłodowska-Curie Action · Running

HOTBIO A holistic approach to training a new generation of scientists in marine biodiscovery

Coordinator
Universitetet I Tromsoe - Norges Arktiske Universitet, Norway
Runs
1 January 2023 to 30 June 2027
Status
Running
EU funding
€2.4m
Total cost
—
Partners
20 organisations in 11 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101072475

What the project is doing

In the project's own words, from its summary on CORDIS.

The HOTBIO consortium will train a new generation of early-stage scientists to take marine microbial natural products from the seabed to the bedside. They will be involved in every stage of the pipeline from microbial isolation through compound purification and identification to making analogues with desirable drug-like properties. They will gain associated skills in access and benefit sharing, intellectual property and entrepreneurship.

Students graduating from HOTBIO will be in a unique position to enter a challenging labour market as they will have received multidisciplinary training at world leading research groups in academia as well as at industry partners. Mentorship will be provided by industrial scientists and recent graduates from the MSCA ITN MarPipe. The HOTBIO consortium consists of eight beneficiaries from seven European countries, including two members from non-academic sectors, that will host ten PhD students.

Three more PhD students hosted by two Swiss associated partners will be funded by the Swiss State Secretariat for Education, Research and Innovation. In addition to secondments at the partners in Europe, students will also get the opportunity to do secondments in low-to-middle income countries (LMICs) in Africa and Asia to get a deeper understanding of how modern research can be done in resource-limited setting. HOTBIO expands a conventional marine biodiscovery pipeline by including computer aided drug design (CADD), chemical synthesis of optimized compounds (i.e. medicinal chemistry), target deconvolution and extensive ADMET profiling.

This will advance the bioactive microbial secondary metabolites to the later stages of preclinical development, and it will also inform the decisions and priorities of what kind of compounds that should be targeted in the initial phase of the drug discovery process. The downstream development will include hit compounds from earlier projects.

Topics

Who is involved

OrganisationCityCountryRole
Universitetet I Tromsoe - Norges Arktiske UniversitetTromsoNorwayCoordinator
Oxford Antibiotic Group GmbHTullnAustriaAssociatedpartner
Abs-InternationalGentBelgiumParticipant
Katholieke Universiteit LeuvenLeuvenBelgiumAssociatedpartner
Universitat ZurichZurichSwitzerlandAssociatedpartner
Universite De LausanneLausanneSwitzerlandAssociatedpartner
Christian-Albrechts-Universitaet Zu KielKielGermanyAssociatedpartner
Helmholtz-Zentrum Fur Ozeanforschung Kiel (geomar)KielGermanyParticipant
Lead Discovery Center GmbHDortmundGermanyParticipant
Ruhr-Universitaet BochumBochumGermanyAssociatedpartner
Fundacion Centro De Excelencia En Investigacion De Medicamentos Innovadores En AndaluciaArmilla GranadaSpainParticipant
Universidad De GranadaGranadaSpainAssociatedpartner
University of GhanaAccraGhanaAssociatedpartner
Sathyabama Institute of Science and TechnologyChennaiIndiaAssociatedpartner
Stazione Zoologica Anton DohrnNapoliItalyParticipant
Universita Degli Studi Di MessinaMessinaItalyAssociatedpartner
Bacto - Tech sp. z o.o.ToruńPolandAssociatedpartner
Uniwersytet Mikolaja KopernikaTorunPolandParticipant
The Open UniversityMilton KeynesUnited KingdomAssociatedpartner
The University Court of the University of AberdeenAberdeenUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI